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Abstract 
Summary/Conclusions 
Having the right model for drug screening is essential for 
predicting compounds that may cause drug-induced liver 
injury. Three dimensional (3D) models offer significant 
improvements over traditional two dimensional monolayer 
cell culture in terms of maintaining morphological and 
functional characteristics of tissue, and may provide a 
better representation of in vitro drug toxicity1. Here we 
demonstrate how Corning HepatoCells, an immortalized 
alternative to primary human hepatocytes, in conjunction 
with Corning Spheroid Microplates can be a utilized for a 
3D drug screen to discover potential hepatotoxins. 
Hepatospheres formed using Corning HepatoCells were 
compared to spheroids formed using alternative 
hepatocyte-like models. Cell viability, urea and albumin 
were measured to assess hepatotoxicity after exposure to 
the SCREEN-WELL Hepatotoxicity library from Enzo Life 
Sciences, a library consisting of 238 compounds with a 
variety of structurally and mechanistically different 
compound classes, as well as nontoxic controls. Selected 
hits identified in the 3D screen, which significantly reduced 
cell viability of the hepatospheres, were then assessed in a 
dose-dependent manner for potency analysis. These 
results demonstrate that Corning HepatoCells, together 
with Corning Spheroid Microplates, are powerful tools that 
can be used for reliable and reproducible 3D hepatotoxicity 
screening. 
• Corning spheroid microplates allow for the formation of consistent 
sized, single spheroids in each well, available in both 96 and 384 
well formats, making them a useful tool for 3D screening. 
 
• Hepatospheres formed using the Corning spheroid microplate are 
amenable to histological analysis. 
 
• The opaque walls and clear, round well-bottom of the spheroid 
microplates allow for luminescent assays to be conducted in the 
plate without the need for a transfer step.  
 
• HepatoCells offer an ideal hepatic cell alternative to commonly 
used HepaRG cells, offering a larger assay window for luminescent 
ATP assays, which is amenable to screening.  
 
• HepatoCells displayed increased or equivalent sensitivity to known 
hepatotoxins tamoxifen, troglitazone and nicardipine upon potency 
analysis, compared to HepG2 and HepaRG cells. 
Representative photomicrographs of HepatoCells,HepG2, and 
HepaRG spheroids after 7 days, seeded at 6,000 cells/well, 200 
cells/well, and 6,000 cells/well respectively (40x). 
Spheroid Size Optimization 
HepatoCells (Corning Cat. No. 354881), HepG2 cells 
(ATCC® Cat. No. HB-8065), and HepaRG™ cells (Life 
Technologies Cat. No. HPRGC10) were seeded at various 
concentrations in 384 well spheroid microplates (Corning 
Cat. No. 3830) to optimize  for the subsequent screens. 
HepatoCells and HepG2 cells were seeded using 50 µL 
Corning Culture Medium for HepatoCells (Corning Cat. No. 
354882) containing 10 % fetal bovine serum (Corning Cat. 
No. 35-010-CV). HepaRG cells were seeded using  
William’s medium (Life Technologies Cat. No. 12551-032)  
supplemented to 1x with HepaRG Thaw, Plate & General 
Purpose Medium Supplement (Life Technologies Cat. No. 
HPRG670) and 1x GlutaMAX (Life Technologies Cat. No. 
35050-061). Medium was changed every other day using 
Corning Culture Medium for HepatoCells without serum for 
HepatoCells and HepG2, or William’s medium 
supplemented to 1x with HepaRG Tox Medium 
Supplement (Life Technologies Cat. No. HPRG630) and 1x 
GlutaMAX for HepaRG. On day 7, spheroids were either 
lysed for nuclei enumeration, assessed for viability using 
Cell Titer-Glo 3D (Promega Cat. No. 354882)  or fixed in 4 
% paraformaldehyde (Boston Bioproducts Cat. No. BM-
155) for cryostat sectioning and H&E staining (assessed at 
the University of New England, Biddeford, Maine). The  
Enzo Screen-Well Hepatotoxicity Library (Enzo Cat. No. 
BML-2851)  and subsequent potency analysis compounds 
were added on day 7 and cultured for an additional 48 
hours. Prior to addition of 30 µL of Cell Titer-Glo 3D for 
viability analysis, medium samples were taken to quantify 
albumin and urea production. Albumin secretion was 
quantified using an ELISA for human albumin (Abnova Cat. 
No. KA0454). Urea production was analyzed via 
colorimetric urea assay kit (BioAssay Systems Cat. No. 
DIUR-500).  
Ratio of relative luminescence units (RLU) to nuclei counts for seeding 
concentration optimization.  Seeding densities were chosen to 
generate high luminescent signals for screening while avoiding necrotic 
core formation. 
Hepatosphere Functionality 
Potency Analysis of Selected Hits 
HepatoCells HepG2 HepaRG 
Representative H&E stained hepatospheres after 7 days of culture. 
HepatoCells HepG2 HepaRG 
Albumin secretion (left) and Urea production (right) after 7 days of 
culture. N = 12 from 3 independent studies, *** p<0.0001 (One way 
ANOVA with Newman-Keuls Multiple Comparison Test). 
 
Hepatotoxicity Screen 
Representative Screen-Well hepatotoxicity library results. Pink line is 
the average response of non responders, blue line is average 
chlorpromazine (positive control) response. Anything below green line 
(5 σ below buffer response) was considered a hit.  
Spheroid Formation 
Potency analysis of selected compounds from the Screen-Well 
hepatotoxicity library, as assessed by Cell Titer-Glo 3D. N= 16 wells per 
concentration. HepatoCells were equally or more sensitive to toxic 
compounds than either HepG2 or HepaRG when assessed in a dose-
dependent fashion.  
Hit Analysis 
HepatoCells HepG2 HepaRG 
Lipid accumulation 
 
7 7 7 
Cholestatic effects 6 8 7 
Mitochondrial toxicity 6 7 4 
Toxic metabolites    3 5 5 
Mallory body formation   2 2 1 
Elevation of liver enzymes  22 25 16 
Inhibition of BSEP   2 3 1 
Representative Screen-Well hepatotoxicity library results from 4 
independent studies. Hits were considered if compound elicited a 
response > 5 σ below buffer response in at least 3 separate screens. 
Results of screen indicate many hepatotoxic hits were observed in all 
three cell types, highlighted by compounds displaying luminescent 
signal below green line on each plot. Of note, HepatoCells display a 
much larger signal window than HepaRG cells. Z' = 0.79, 0.57, and 
0.80 for HepatoCells, HepG2, and HepaRG, respectively. 
TC50 Values Tamoxifen Troglitazone Nicardipine 
HepatoCells 1.4e-005 3.2e-005 4.8e-005 
HepG2 1.1e-005 2.1e-005 2.7e-005 
HepaRG 4.3e-005 - 0.013 
ATP Per Nuclei
H
ep
at
oC
el
ls
 6
00
0
H
ep
at
oC
el
ls
 8
00
0
H
ep
at
oC
el
ls
 1
00
00
H
ep
G
2 
 2
00
H
ep
G
2 
50
0
H
ep
G
2 
10
00
H
ep
aR
G
 6
00
0
H
ep
aR
G
 8
00
0
H
ep
aR
G
 1
00
00
0
2
4
6
Seeding Density/Well
R
L
U
/N
u
cl
e
i
Albumin Secreation
HepatoCells HepG2 HepaRG
0.0
0.5
1.0
1.5
2.0
2.5
***
***

g
/
L
Urea Production
HepatoCells HepG2 HepaRG
0.000
0.005
0.010
0.015

g
/
L
Cell Viability
-6.0 -5.5 -5.0 -4.5 -4.0 -3.5-80000
-60000
-40000
-20000
0
20000
HepatoCells
HepG2
HepaRG
log[Tamoxifen] (M)
R
L
U
Cell Viability
-6.0 -5.5 -5.0 -4.5 -4.0 -3.5
-60000
-40000
-20000
0
20000
HepatoCells
HepG2
HepaRG
log[Troglitazone] (M)
R
L
U
Cell Viability
-6.0 -5.5 -5.0 -4.5 -4.0 -3.5-80000
-60000
-40000
-20000
0
20000
HepatoCells
HepG2
HepaRG
log[Nicardipine] (M)
R
L
U
